We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.49B
Turnover
10.26%
1-Year Est. Return
208.7%
This Fund
S&P 500
This Quarter
Est. Return
-16.16%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.06B
AUM Growth
-$377M
(-26%)
Cap. Flow
-$48.8M
Cap. Flow
% of AUM
-4.62%
Top 10 Holdings %
Top 10 Hldgs %
61.75%
Holding
64
New
2
Increased
7
Reduced
31
Closed
8
Avg Time Held
3.6
years
Top 10 Avg Time Held
1.7
years
Top 20 Avg Time Held
1.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amicus Therapeutics
FOLD
|
+$22.9M |
| 2 |
iRhythm Holdings
IRTC
|
+$6.02M |
| 3 |
Solid Biosciences
SLDB
|
+$6.01M |
| 4 |
Immunome
IMNM
|
+$5.12M |
| 5 |
Insulet
PODD
|
+$4.75M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Akero Therapeutics
AKRO
|
+$12.5M |
| 2 |
Boston Scientific
BSX
|
+$12M |
| 3 |
Stryker
SYK
|
+$11M |
| 4 |
Intuitive Surgical
ISRG
|
+$8.84M |
| 5 |
Ardelyx
ARDX
|
+$7.99M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
DELISTED
Ventyx Biosciences
VTYX
| $1.81M | 0.17% |
1,569,793
+1,445,615
| +1,164% | +$2.48M |
2022 Q3
10 quarters
|
|
52
DELISTED
Astria Therapeutics
ATXS
| $1.44M | 0.14% |
269,078
-77,200
| -22% | -$540K |
2024 Q3
2 quarters
|
|
53
Invivyd
IVVD
$197M
| $1.38M | 0.13% |
2,285,320
-726,934
| -24% | -$652K |
2021 Q3
14 quarters
|
|
54
Boundless Bio
BOLD
$54.3M
| $1.1M | 0.1% |
725,204
-15,000
| -2% | -$31.1K |
2024 Q1
4 quarters
|
|
55
Kalaris Therapeutics
KLRS
$52.1M
| $666K | 0.06% |
82,955
| – | – |
2020 Q3
18 quarters
|
|
56
DELISTED
Allakos
ALLK
| $195K | 0.02% |
856,615
-2,158,482
| -72% | -$975K |
2018 Q3
26 quarters
|
|
57
AC Immune
ACIU
$244M
| – | – |
-1,034,299
| Closed | -$2.79M | – |
|
|
ADAP
58
DELISTED
Adaptimmune Therapeutics
ADAP
| – | – |
-715,607
| Closed | -$385K | – |
|
|
59
Ardelyx
ARDX
$844M
| – | – |
-1,576,259
| Closed | -$7.99M | – |
|
60
DELISTED
HOOKIPA Pharma
HOOK
| – | – |
-106,376
| Closed | -$214K | – |
|
|
61
Intuitive Surgical
ISRG
$151B
| – | – |
-16,943
| Closed | -$8.84M | – |
|
62
Stereotaxis
STXS
$105M
| – | – |
-1,799,465
| Closed | -$4.1M | – |
|
|
63
Stryker
SYK
$112B
| – | – |
-30,676
| Closed | -$11M | – |
|
|
ACHL
64
DELISTED
Achilles Therapeutics
ACHL
| – | – |
-1,608,089
| Closed | -$1.83M | – |
|
Similar funds
FCM
MM
WA
ACB
LCS
GAM
MFWP
PMG
Redmile Group's Q1 2025 Portfolio in Review
As of Q1 2025, Redmile Group held 64 positions worth $1.06B, down 26% from $1.43B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Redmile Group withdrew a net $48.8M in Q1 2025, closing 8 positions and reducing 31 holdings. Its most notable exit was Stryker, an estimated $11M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Redmile Group opened a new position in iRhythm Holdings worth $5.95M.
- Redmile Group's largest Q1 2025 buy was iRhythm Holdings: 56,844 shares worth $5.95M.
- Redmile Group added most to Amicus Therapeutics in Q1 2025, an estimated $22.9M increase.
- Redmile Group's biggest Q1 2025 reduction was Akero Therapeutics, cutting an estimated $12.5M.
- Redmile Group fully exited Stryker in Q1 2025, selling an estimated $11M.
- Redmile Group's ten largest holdings make up 62% of its $1.06B portfolio in Q1 2025.
- Redmile Group opened 2 new positions and closed 8 in Q1 2025.
- Redmile Group's portfolio value fell 26% quarter-over-quarter to $1.06B.
Based on Redmile Group's 13F filing for Q1 2025, filed 15 May 2025.